Biotech startups heavily rely on venture capital for funding, as drug development is costly and often years away from profitability. The investment landscape has evolved, with significant increases in funding, particularly for cancer and immune disease treatments, and a trend towards larger funding rounds for later-stage biotechs. A database tracking these investments highlights the active role of 23 venture capital firms in shaping the industry.
